The absolute bioavailability and pharmacokinetics of three formulations of ondansetron hydrochloride 24 mg—an oral tablet, an intravenous solution, and an
The objective of this study was to determine the feasibility and develop a formulation for an extemporaneously prepared ondansetron suppository
The dissolution profile of the ondansetron-loaded NLC suppository depicts biphasic behavior of firstly burst release then slow release was observed
Cite this: Pharmacokinetics of Three Formulations of Ondansetron Hydrochloride in Healthy Volunteers: 24-Mg Oral Tablet, Rectal Suppository, and i
Ondansetron is used to prevent nausea and vomiting that may be caused by
Following administration of ondansetron suppository, plasma ondansetron concentrations
Children younger than 2 years of age—Use and dose must be determined by your doctor
Measurements and Main Results
The suppository is to be inserted into the rectum
Women had a consistently higher AUC for all three formulations than men (p<0
1: In vitro drug release study of conventional suppository of ondansetron
Twelve healthy, nonsmoking volunteers (six men and six women) were given ondansetron in a study with a three-way cross
Each 5 mL of ZOFRAN oral solution contains 5 mg of ondansetron hydrochloride dihydrate equivalent to 4 mg of ondansetron
Suppositories containing 16 mg of ondansetron were prepared by fusion method
Daily fractions to abdomen: Administer 8 mg PO 1-2 hr Ondansetron is the therapeutically active ingredient in Zofran suppositories and in Zofran Zydis wafers
6 hours and after intravenous dosing 2